

Special Issue

Multi-omics Approaches for Biomarker Discovery in Early Ovarian Cancer Diagnosis

Message from the Guest Editor

Ovarian cancer presents a significant challenge in oncology, often diagnosed at advanced stages with limited treatment options. The emergence of multi-omics approaches offers promising avenues for early disease detection and personalized treatment strategies. This Special Issue explores the integration of diverse molecular data sets to identify robust biomarkers for early ovarian cancer diagnosis. Researchers can uncover molecular signatures indicative of ovarian cancer onset and progression by leveraging genomics, transcriptomics, proteomics, metabolomics, and other omics platforms. By exploring the complex interplay between the biological pathways and molecular alterations of ovarian cancer, we will enable more effective personalized medicine interventions and improved patient outcomes. Furthermore, bioinformatics approaches, including traditional pipelines and new artificial intelligence models, may be crucial for analyzing multi-omics data required for biomarker discovery and clinical decision-making support.


Guest Editor

Dr. Abedalrhman Alkhateeb

Computer Science Department, Lakehead University, 955 Oliver Rd,
Thunder Bay, ON P7B 5E1, Canada

Deadline for manuscript submissions

closed (25 October 2024)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/200522

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).